CYP2D6 predicted metabolizer status and safety in adult patients with attention‐deficit hyperactivity disorder participating in a large placebo‐controlled atomoxetine maintenance of response clinical trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|10|1167-1174

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.10, 2015-10, pp. : 1167-1174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cognitive–behavioural therapy for adult attention‐deficit hyperactivity disorder: a proof of concept randomised controlled trial

By  

ACTA PSYCHIATRICA SCANDINAVICA, Vol. 137, Iss. 2, 2018-02 ,pp. : 125-137

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prescribing of Drugs for Attention-Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway

By  

European Addiction Research, Vol. 20, Iss. 2, 2013-09 ,pp. : 59-65

Karger

Access to resources Recommend Favorite

Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study

By Bakken Rosalie J.   Paczkowski Martin   Kramer Hal P.   Axelson Alan A.   Williams David W.   Malcolm Sandra K.   Sumner Calvin R.   Kelsey Douglas K.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder

By Turgay Atilla  

Therapy, Vol. 3, Iss. 1, 2006-01 ,pp. : 19-38

Future Medicine

Access to resources Recommend Favorite

Meaningful Use and Clinical Utility of Preemptive Pharmacogenetic Testing: (Re)View From a CYP2D6 Poor Metabolizer

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 119-121

John Wiley & Sons Inc

Access to resources Recommend Favorite